BACKGROUND AND CHALLENGE
As the COVID-19 pandemic has caused major disruptions in the biopharma industry, PPD has been fortunate enough to weather the storm with relative ease. This is in large part a testament to our internal resourcing capabilities that we have recently begun to commercialize as the PPD FSP Source capacity management solution. Even though it’s difficult to compare these current unprecedented times to typical operating conditions, our own experiences can broadly serve as a first “case study” for PPD FSP Source.

CHALLENGES
Out of a lack of accurate reporting and/or capacity planning, many biopharma companies have either over-hired or failed to adjust capacity fast enough. This has resulted in:
- Workforce layoffs
- Significant financial impacts
- Inability to gain COVID-19 study contracts

SOLUTION
With the benefit of our capacity management systems and practices, PPD was better equipped to handle the uncertainties of COVID-19.
- Minimal disruption to the workforce.
  Accurate forecasting and analysis has kept us prepared even during these turbulent circumstances.
- Able to staff up quickly. We were able to fill openings on a global basis in a one-month period.
- Responsive to influx of COVID-19 trials. PPD has had the resources needed to win and execute coronavirus-related studies as they quickly come online.

RESULTS
PPD’s capacity management expertise has proven invaluable during the COVID-19 crisis. Upon hearing about our response and how well we have treated our employees, one of our customers cited that as a reason to do more work with PPD. Offering the same level of access to high-quality talent resourcing, forecasting and analysis, PPD FSP Source is now available to help position you for success.